Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Adams, 1987, Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic β cells, Nature, 325, 223, 10.1038/325223a0 Bergers, 1999, Effects of angiogenesis inhibitors on multistage carcinogenesis in mice, Science, 284, 808, 10.1126/science.284.5415.808 Bergers, 2000, Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis, Nat. Cell Biol., 2, 737, 10.1038/35036374 Bergers, 2003, Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors, J. Clin. Invest., 111, 1287, 10.1172/JCI200317929 Brantley, 2002, Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo, Oncogene, 21, 7011, 10.1038/sj.onc.1205679 Broxterman, 2003, Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences, Drug Resist. Updat., 6, 111, 10.1016/S1368-7646(03)00026-8 Cheng, 2003, Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors, Neoplasia, 5, 445, 10.1016/S1476-5586(03)80047-7 Christofori, 1995, Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis, Mol. Endocrinol., 9, 1760 Compagni, 2000, Fibroblast growth factors are required for efficient tumor angiogenesis, Cancer Res., 60, 7163 Daniel, 2003, Immune enhancement of skin carcinogenesis by CD4+ T cells, J. Exp. Med., 197, 1017, 10.1084/jem.20021047 Daniel, 2005, CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer, Cancer Res., 65, 2018, 10.1158/0008-5472.CAN-04-3444 de Visser, 2005, De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent, Cancer Cell, 7, 411, 10.1016/j.ccr.2005.04.014 Dougher-Vermazen, 1994, Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor, Biochem. Biophys. Res. Commun., 205, 728, 10.1006/bbrc.1994.2726 Efrat, 1988, β-cell lines derived from transgenic mice expressing a hybrid insulin gene-oncogene, Proc. Natl. Acad. Sci. USA, 85, 9037, 10.1073/pnas.85.23.9037 Ferrara, 2003, The biology of VEGF and its receptors, Nat. Med., 9, 669, 10.1038/nm0603-669 Hanahan, 1985, Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes, Nature, 315, 115, 10.1038/315115a0 Hanahan, 1996, Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis, Cell, 86, 353, 10.1016/S0092-8674(00)80108-7 Hattori, 2002, Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment, Nat. Med., 8, 841, 10.1038/nm740 Hiratsuka, 1998, Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice, Proc. Natl. Acad. Sci. USA, 95, 9349, 10.1073/pnas.95.16.9349 Holash, 1999, Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF, Science, 284, 1994, 10.1126/science.284.5422.1994 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N. Engl. J. Med., 350, 2335, 10.1056/NEJMoa032691 Inoue, 2002, VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis, Cancer Cell, 1, 193, 10.1016/S1535-6108(02)00031-4 Jolicoeur, 1994, T cell tolerance towards a transgenic β cell antigen and transcription of endogenous pancreatic genes in the thymus, Proc. Natl. Acad. Sci. USA, 91, 6707, 10.1073/pnas.91.14.6707 Joyce, 2004, Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis, Cancer Cell, 5, 443, 10.1016/S1535-6108(04)00111-4 Joyce, 2005, A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer, Oncogene, 24, 4037, 10.1038/sj.onc.1208602 Kerbel, 2001, Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches, Cancer Metastasis Rev., 20, 79, 10.1023/A:1013172910858 Klement, 2000, Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity, J. Clin. Invest., 105, R15, 10.1172/JCI8829 Leenders, 2004, Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option, Clin. Cancer Res., 10, 6222, 10.1158/1078-0432.CCR-04-0823 Luttun, 2002, Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1, Nat. Med., 8, 831, 10.1038/nm731 Matsumoto, 2005, VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis, EMBO J., 24, 2342, 10.1038/sj.emboj.7600709 Miles, 1952, Vascular reactions to histamine, histamine-liberator and leukotaxine in the skin of guinea-pigs, J. Physiol., 118, 228, 10.1113/jphysiol.1952.sp004789 Miller, 2003, The Snark is a Boojum: the continuing problem of drug resistance in the antiangiogenic era, Ann. Oncol., 14, 20, 10.1093/annonc/mdg033 Miller, 2005, Can tumor angiogenesis be inhibited without resistance?, EXS, 94, 95 Mombaerts, 1992, RAG-1-deficient mice have no mature B and T lymphocytes, Cell, 68, 869, 10.1016/0092-8674(92)90030-G Parangi, 1996, Antiangiogenic therapy of transgenic mice impairs de novo tumor growth, Proc. Natl. Acad. Sci. USA, 93, 2002, 10.1073/pnas.93.5.2002 Passaniti, 1992, A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor, Lab. Invest., 67, 519 Pennacchietti, 2003, Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene, Cancer Cell, 3, 347, 10.1016/S1535-6108(03)00085-0 Pezzella, 1997, Non-small-cell lung carcinoma tumor growth without morphological evidence of neo-angiogenesis, Am. J. Pathol., 151, 1417 Pugh, 2003, Regulation of angiogenesis by hypoxia: role of the HIF system, Nat. Med., 9, 677, 10.1038/nm0603-677 Rabbany, 2003, Molecular pathways regulating mobilization of marrow-derived stem cells for tissue revascularization, Trends Mol. Med., 9, 109, 10.1016/S1471-4914(03)00021-2 Ryschich, 2002, Transformation of the microvascular system during multistage tumorigenesis, Int. J. Cancer, 97, 719, 10.1002/ijc.10074 Sawano, 2001, Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans, Blood, 97, 785, 10.1182/blood.V97.3.785 Shibuya, 2001, Structure and function of VEGF/VEGF-receptor system involved in angiogenesis, Cell Struct. Funct., 26, 25, 10.1247/csf.26.25 Steeg, 2003, Angiogenesis inhibitors: motivators of metastasis?, Nat. Med., 9, 822, 10.1038/nm0703-822 Yang, 2003, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer, N. Engl. J. Med., 349, 427, 10.1056/NEJMoa021491 Yu, 2002, Effect of p53 status on tumor response to antiangiogenic therapy, Science, 295, 1526, 10.1126/science.1068327